Abstract: The invention relates to an in vitro diagnosis device (10) for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterized in that it comprises: a substrate (12); and a hydrophobic porous membrane (14) having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone (16) intended to receive the sample. The invention also relates to the uses of said device in immunohematology.

Abstract: The invention relates to an in vitro diagnosis device for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterized in that it comprises: a substrate; and a hydrophobic porous membrane having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone intended to receive the sample. The invention also relates to the uses of said device in immunohematology.

Abstract: The invention relates to an in vitro diagnosis device (10) for the detection of at least one reaction between an erythrocytic phenotype antigen and an antibody specifically directed against said antigen in a sample of blood or one of the components thereof. The device is characterised in that it comprises: a substrate (12); and a hydrophobic porous membrane (14) having a thickness of between 0.5 mm and 1.5 mm and a pore diameter of between 2 and 30 ?m, said membrane comprising at least one hydrophilic reaction zone (16) intended to receive the sample. The invention also relates to the uses of said device in immunohematology.

Abstract: A method of selecting/identifying an active agent for modifying the shape of keratin fibers, includes the following steps: a) culturing mammalian cells, b) adding a test substance to the mammalian cell culture, c) after incubation thereof, assaying the amount of glycosaminoglycans (GAGs) in the mammalian cells or in the mammalian cell culture medium, d) comparing the amount of GAGs measured in step c) with that measured starting from a control culture of mammalian cells, obtained under the same conditions, but in the absence of test substance, and selecting the substances for which the amount of GAGs is modified by at least a factor of 0.5 relative to the amount measured in the control culture; the active agents thus selected/identified are useful for modifying the shape of keratin fibers.